NCT01158157Phase 3Completed

VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV

Study sponsor: Emergent BioSolutions

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Primary completion2012-02-14Actual
Enrollment · participants25Actual
Source updated2024-03-18Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.